<DOC>
	<DOCNO>NCT01076400</DOCNO>
	<brief_summary>This study conduct two part . Part 1 determine whether administration MK1775 combination topotecan cisplatin generally well-tolerated cause clinical objective response patient cervical cancer . Part 1 also define recommend Phase 2 dose maximum tolerate dose ( MTD ) combination MK1775 topotecan cisplatin . Part 2 study evaluate whether treatment MK1775 combination topotecan cisplatin cause improvement progression-free survival ( PFS ) compare treatment topotecan cisplatin alone evaluate tolerability combination treatment .</brief_summary>
	<brief_title>A Study MK1775 Combination With Topotecan/Cisplatin Patients With Cervical Cancer ( 1775-008 )</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Patient advance , metastatic , recurrent squamous cell , adenosquamous , adenocarcinoma uterine cervix ( Stage II IVb ) Patient receive cisplatin combination radiation initial adjuvant treatment cervical cancer Patient receive treatment cancer follow cisplatinbased chemoradiation target therapy except noncytotoxic target therapy Recurrence must least 6 month post cisplatinbased chemotherapy Patient measurable disease Patient 's performance status Eastern Cooperative Oncology Group ( ECOG ) Performance Scale less equal 1 Patient negative pregnancy test within 72 hour first dose study medication Patient chemotherapy , radiotherapy , biological therapy within 6 month enter study Patient history vascular thrombotic event vascular reconstruction Patient active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Patient primary CNS tumor Patient require use medication product metabolize , inhibit induce CYP3A4 ( Cytochrome P450 3A4 ) Patient expect reproduce within duration study pregnant breastfeeding Patient know Human Immunodeficiency Virus ( HIV ) positive Patient know active Hepatitis B C Patient know history interstitial lung disease pulmonary fibrosis Patient symptomatic ascites pleural effusion Patient clinical history suggestive LiFraumeni Syndrome</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>